{
    "clinical_study": {
        "@rank": "45178", 
        "arm_group": {
            "arm_group_label": "Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)", 
            "arm_group_type": "Other", 
            "description": "Evaluations of renal and cardiac function"
        }, 
        "brief_summary": {
            "textblock": "No investigational drug will be administered in this study for the treatment of Fabry\n      disease.\n\n      This will be a multicenter, multinational, non-treatment, cross-sectional study of young\n      male patients with Fabry disease who have not yet initiated interventional treatment for\n      this disease. The study will consist of a screening visit(s), a clinical investigation\n      visit(s), and a follow-up phone contact.\n\n      The objectives of the study are:\n\n        -  To document renal function and other Fabry disease manifestations across age in\n           treatment-na\u00efve, young male patients with Fabry disease.\n\n        -  To provide a reference group for comparison with interventional clinical trials of\n           Fabry disease.\n\n      The duration of each patient's participation in the study, inclusive of the screening visit\n      and follow-up phone contact, will be approximately 12 weeks."
        }, 
        "brief_title": "A Study of Renal Function in Treatment-na\u00efve, Young Male Patients With Fabry Disease", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Fabry Disease", 
        "condition_browse": {
            "mesh_term": "Fabry Disease"
        }, 
        "detailed_description": {
            "textblock": "Patients who meet all eligibility criteria based on screening assessments will be scheduled\n      to return to the clinic for assessments of renal function and other disease-related\n      parameters, which may be scheduled over one or more clinical investigation visits. The\n      clinical investigation visit(s) will be scheduled such that renal and cardiac assessments\n      occur after the required medication washout (see exclusion criterion); other procedures may\n      be performed either before or after the medication washout, at the discretion of the\n      investigator.\n\n      Up to 100 patients will be enrolled in the study, including a minimum of 15 patients in each\n      of the following age groups (based on age at screening): 5 to 11 years, 12 to 17 years, and\n      18 to 25 years.\n\n      All patients will be encouraged to enroll in the Fabry Registry (NCT00196742) for continued\n      follow-up after completion of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient and/or their parent/legal guardian is willing and able to provide signed\n             informed consent.  If the patient is below the age of consent per local guidelines,\n             he is willing to provide assent, if deemed able to do so.\n\n          -  The patient must have a confirmed diagnosis of Fabry disease as documented by\n             leukocyte \u03b1-galactosidase A (\u03b1GAL) of <4 nmol/hr/mg leukocyte (preferred assay;\n             results from a central laboratory). If the leukocyte \u03b1GAL activity assay is difficult\n             to obtain, the patient may be enrolled based on documented plasma \u03b1GAL <1.5\n             nmol/hr/mL (results from a central laboratory), with the agreement of the Genzyme\n             Medical Monitor.\n\n        Exclusion Criteria:\n\n          -  Patient has received prior treatment with enzyme replacement therapy (ERT) or oral\n             pharmacological chaperone therapy for Fabry disease.\n\n          -  Patient has received an investigational drug within 30 days of the screening visit.\n\n          -  Patient is receiving any of the following medications and is clinically unable or\n             unwilling to temporarily discontinue treatment with these medications for the\n             indicated washout period prior to the renal function assessments until completion of\n             these assessments:\n\n               -  Angiotensin converting enzyme inhibitors or angiotensin receptor blockers (6\n                  week washout);\n\n               -  Non-steroidal anti-inflammatory drugs (3 day washout).\n\n               -  NOTE: Patients who are on chronic dialysis or have had a kidney transplant\n                  will not be required to discontinue the above medications because renal function\n                  assessments will not be performed in these patients.\n\n          -  Patient has any contraindication mentioned in the labeling of iohexol. NOTE: patients\n             with an eGFR <30 mL/min/1.73m^2 and patients who are on chronic dialysis or have had\n             a kidney transplant may be enrolled irrespective of any contraindication to iohexol\n             because iGFR will not be measured in these patients.\n\n          -  Patient has any medical condition or extenuating circumstance which, in the opinion\n             of the Investigator, could interfere with the patient's ability to complete all study\n             procedures, or with the interpretation of study results (e.g., diabetes mellitus).\n\n          -  The patient and/or their parent or legal guardian, in the opinion of the\n             Investigator, is unable to adhere to the requirements of the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839526", 
            "org_study_id": "AGAL19110", 
            "secondary_id": [
                "2012-001966-14", 
                "MSC 12711"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)", 
            "description": "Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.", 
            "intervention_name": "Iohexol", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Fabry disease", 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30033"
                    }, 
                    "name": "Investigational Site Number 840006"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229-3039"
                    }, 
                    "name": "Investigational Site Number 840003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22030"
                    }, 
                    "name": "Investigational Site Number 840002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "532261"
                    }, 
                    "name": "Investigational Site Number 840007"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium"
                    }, 
                    "name": "Investigational Site Number 056001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bron Cedex", 
                        "country": "France", 
                        "zip": "69677"
                    }, 
                    "name": "Investigational Site Number 250002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garches", 
                        "country": "France", 
                        "zip": "92380"
                    }, 
                    "name": "Investigational Site Number 250001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergen", 
                        "country": "Norway", 
                        "zip": "5021"
                    }, 
                    "name": "Investigational Site Number 578001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "zip": "08916"
                    }, 
                    "name": "Investigational Site Number 724001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Girona", 
                        "country": "Spain", 
                        "zip": "17007"
                    }, 
                    "name": "Investigational Site Number 724002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC1N 3JH"
                    }, 
                    "name": "Investigational Site Number 826002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW1 2PJ"
                    }, 
                    "name": "Investigational Site Number 826004"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "France", 
                "Norway", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Cross-sectional Study of Renal Function in Treatment-na\u00efve, Young Male Patients With Fabry Disease", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_contact_backup": {
            "email": "medinfo@genzyme.com", 
            "last_name": "Medical Information", 
            "phone": "617-252-7832"
        }, 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Tests are performed only for patients who are not on chronic dialysis and/or have not received a kidney transplant.", 
                "measure": "Glomerular Filtration Rate Estimated from Serum Creatinine (eGFR)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Week 8"
            }, 
            {
                "description": "Assessment of iGFR will NOT be performed if a patient is on chronic dialysis, has had a kidney transplant, or has a screening eGFR <30 mL/min/1.73 m^2 or presents any contraindication mentioned in the labeling of iohexol (Omnipaque\u2122 300).", 
                "measure": "Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Week 8"
            }, 
            {
                "measure": "Protein Excretion Assessed from Three First-Morning Urine Voids", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839526"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessed by electrocardiogram (ECG) and echocardiography", 
            "measure": "Cardiovascular Function", 
            "safety_issue": "No", 
            "time_frame": "Day 1 to Week 8"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}